Aldosterone antagonists after ACS are indicated for which patients?

• A. All patients immediately
• B. On beta-blocker and ACEI/ARB with heart failure and diabetes or heart failure symptoms after ACS, who are already on ACE/ARB and beta-blocker and still having events
• C. Never in ACS
• D. Only if there is hypotension

Answer: (B)

The key idea is that aldosterone antagonists are added after an acute coronary syndrome only for a specific high‑risk group: patients with reduced left‑ventricular systolic function who have heart failure symptoms or diabetes, and who are already on optimal standard therapy (ACE inhibitors or ARBs and beta‑blockers). Trials like EPHESUS showed that in this subgroup, adding an aldosterone antagonist after ACS reduces mortality and cardiovascular events. So the best choice describes patients who are on beta‑blocker and ACEI/ARB with heart failure and diabetes or heart failure symptoms after ACS, on stable standard therapy, and still experiencing events. This is not indicated for all post‑ACS patients, nor is it reserved for those with hypotension, and it’s not used in patients without this specific LV dysfunction and HF/DM profile. Additionally, when using these drugs, monitor potassium and renal function due to hyperkalemia and kidney effects.